当前位置:首页 > 关于我们 > 创投导师 > 武海波

武海波 | Wu Haibo


图片.png

武海波
• 毕业于北京大学
• 现任北京精诚通医药科技有限公司创始人、董事长,中国药品监督管理研究会药品监管研究国际交流专业委员会委员,中国医药生物技术协会常务理事,中国医药质量管理协会CRO分会副主任委员,中国药物临床试验机构联盟副秘书长等
在临床研究领域深耕20年,擅长临床试验管理,医药及器械相关产品注册管理,医药领域的技术与市场咨询,医药产业政策咨询等,首创智能CRO平台,有深厚的行业背景和从业经验。尤其在精神神经领域,成就突出。
Wu Haibo
Graduated from Peking University
Currently, he is the founder and chairman of Beijing Giant Pharmaceutical Technology Co., Ltd., member of International Exchange Committee of drug regulatory research of China pharmaceutical regulatory Research Association, executive director of China Pharmaceutical Biotechnology Association, deputy chairman of CRO branch of China Pharmaceutical Quality Management Association, and Deputy Secretary General of China pharmaceutical clinical trial institutions Alliance
He has been engaged in clinical research for 20 years. He is good at clinical trial management, registration management of pharmaceutical and device related products, technology and market consultation in the pharmaceutical field, and policy consultation in the pharmaceutical industry. He is the first one to create an intelligent CRO platform with profound industry background and working experience, especially in the field of psychoneurosis.

0.175650s